Thermo Fisher Scientific's solution for cell and gene therapies involves a combination of cold chain logistics, serialization compliance, and distribution

Researchers at the University of Toronto have identified hundreds of new proteins that could play a role in cystic fibrosis, and which may shed light on why some patients respond better than others to current therapies.

Pacific Biosciences reported after the close of the market on Tuesday that its fourth quarter 2021 revenues grew 33 percent year over year, while its full-year revenues jumped 65 percent.

On 12 February, the second meeting between the Mainland and Hong Kong on the COVID-19 outbreak as held in Shenzhen as the COVID-19 continued to spread in Hong Kong and confirmed cases continued to soar.

At the end of the reporting period, the total assets of Wantai Biopharmwere CNY 7.047 billion, an increase of 101.13% over the beginning of the period.

Olink reported before the opening of the market Monday that its Q4 revenues rose 61 percent.

A globally renowned expert in autoimmune diseases and systemic lupus erythematosus (SLE) at the University of Houston has identified potential biomarkers for neuropsychiatric symptoms of lupus.

The continuous outbreak of the 2021 epidemic has drawn attention to the issue of upstream raw materials in China's IVD industry.

Bruker on Friday reported that its fourth quarter revenues were up 9 percent year over year, driven by growth across almost all of the firm's business segments.

Along with the development of new therapies, advances in technologies that enable earlier diagnosis of cancer are critical to improve patient outcomes.

On January 30, China Telecom Medical Health Technology Co., Ltd. was established with a registered capital of CNY 200 million.

Illumina reported after the close of the market on Thursday that its fourth quarter 2021 revenues rose 26 percent year over year, narrowly beating its own forecast last month of 25 percent growth.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced financial results for the fourth quarter and year ended December 31, 2021.

Jiangsu Mole Bioscience obtained the approval of the Helicobacter pylori 23S rRNA gene and gyrA gene mutation test kit (fluorescence PCR method) by NMPA. This kit is the first product in China that can simultaneously detect clarithromycin and levofloxacin resistance genes.

Roche on Thursday reported a 29 percent year-over-year increase in sales in its diagnostics division for full-year 2021, driven by momentum in the base business and continued demand for COVID-19 testing.